title: Increased density but not prevalence of gametocytes following drug treatment of Plasmodium falciparum.
abstract: We monitored post-treatment Plasmodium falciparum among patients treated with chloroquine (CQ) and sulfadoxine-pyrimethamine (SP; Fansidar in a village in eastern Sudan. Parasites were examined on day 0 (pre-treatment), day 7, day 14 and day 21 (post-treatment) during the transmission season. A further sample was taken 2 months later (day 80) at the start of the dry season. Asexual forms and gametocytes were detected by microscopy, and reverse transcriptase polymerase chain reaction (RT-PCR) was used to detect expression of gametocyte-specific proteins pfs 25 and pfg 377. Gametocyte carriage, as revealed by microscopy, increased significantly following CQ and SP treatment, reaching a maximum between days 7 and 14. When measured by RT-PCR, however, there was no significant difference in gametocyte rate between day 0 and days 7 or 14. RT-PCR gametocyte rates dropped dramatically by day 80 post treatment but were still 33% and 8% in the CQ- and SP-treated group at this time. Alleles associated with drug resistance of P. falciparum to chloroquine (the chloroquine resistance transporter, pfcrt, and multidrug resistance, pfmdr1) and to pyrimethamine (dihydrofolate reductase, dhfr) were seen at a high frequency at the beginning of treatment and increased further through time following both drug treatments. Infections with drug-resistant parasites tended to have higher gametocyte prevalence than drug-sensitive infections.
authors.affiliation: Sudan Atomic Energy Commission, Khartoum, Sudan.
authors.forename: Eltayeb
authors.initials: E
authors.lastname: Ali
authors.forename: Margaret J
authors.initials: MJ
authors.lastname: Mackinnon
authors.forename: Abdel-Muhsin A
authors.initials: AM
authors.lastname: Abdel-Muhsin
authors.forename: Salah
authors.initials: S
authors.lastname: Ahmed
authors.forename: David
authors.initials: D
authors.lastname: Walliker
authors.forename: Hamza A
authors.initials: HA
authors.lastname: Babiker
mesh_terms: D000293:Adolescent; D000328:Adult; D000818:Animals; D000962:Antimalarials / Q000627:therapeutic use*; D002648:Child; D002738:Chloroquine / Q000627:therapeutic use*; D004338:Drug Combinations; D004351:Drug Resistance; D006801:Humans; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000453:epidemiology / Q000469:parasitology; D008875:Middle Aged; D010963:Plasmodium falciparum / Q000187:drug effects* / Q000254:growth & development; D015995:Prevalence; D011739:Pyrimethamine / Q000627:therapeutic use*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013397:Sudan; D013413:Sulfadoxine / Q000627:therapeutic use*
chemical_list: D000962:Antimalarials; D004338:Drug Combinations; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D002738:Chloroquine; D011739:Pyrimethamine